🤝 BigHat will utilize Synaffix’s advanced ADC technology along with its ML platform, Milliner™, for a new drug pipeline.
🚀 This partnership aims to enhance the efficacy and safety of ADCs while streamlining the development process for future clinical applications.
Introduction:
The collaboration between Synaffix and BigHat Biosciences represents a significant advancement in the field of antibody-drug conjugates (ADCs). This partnership leverages machine learning technology to enhance the design and development of next-generation ADCs aimed at improving targeted therapies for various diseases.
- Synaffix has licensed its innovative ADC technology to BigHat Biosciences, combining their platforms to advance ADC development.
- The collaboration provides BigHat with access to Synaffix’s site-specific ADC technology, enhancing their capacity to transform antibodies into specialized therapeutic products.
- BigHat’s AI-driven platform, Milliner™, integrates machine learning and synthetic biology for efficient antibody design, facilitating rapid candidate development and validation.
- This alliance is pivotal in advancing BigHat’s next-gen ADC program, which is focused on optimizing drug delivery to tumor cells while enhancing safety and efficacy.
- Lonza plays a critical supporting role by providing comprehensive development and manufacturing services, streamlining the path from DNA to investigational new drug (IND) applications.
Conclusion:
The partnership between Synaffix and BigHat Biosciences exemplifies the integration of advanced biotechnological methods and artificial intelligence in drug development. As they progress towards clinical-stage trials, this collaboration may significantly enhance the efficacy of cancer treatments and potentially lead to safer therapeutic options in the field of ADCs.
